BioNexus Gene Lab (BGLC) Shares Outstanding (2018 - 2026)

BioNexus Gene Lab has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) changed N/A year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (changed N/A YoY) and the FY2025 annual result came in at $1.9 million, up 4.2% from the prior year.
• Shares Outstanding (Entity) advanced to $2.4 million in Q1 2026 per BGLC's latest filing, from $1.9 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $17.4 million in Q2 2023 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $2.7 million and a median of $1.8 million in 2023 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) jumped 1100.05% in 2023, then sank 89.83% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $1.4 million in 2022, then grew by 22.05% to $1.8 million in 2023, then gained by 0.85% to $1.8 million in 2024, then advanced by 4.2% to $1.9 million in 2025, then jumped by 30.2% to $2.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $2.4 million, $1.9 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.